醒脑静注射液治疗缺血性脑卒中的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 醒脑静注射液治疗缺血性脑卒中的临床观察
TITLE:
摘要: 目的:观察醒脑静注射液治疗缺血性脑卒中的疗效和安全性。方法:110例缺血性脑卒中患者随机均分为对照组和观察组。两组患者均予以控制血压、血糖、降脂,给予阿司匹林肠溶片、胞磷胆碱、依达拉奉,视病情轻重适当给予甘露醇等常规治疗。在此基础上,对照组患者给予0.9%氯化钠注射液250 ml,静脉滴注,每日1次;观察组患者给予醒脑静注射液20 ml,加入0.9%氯化钠注射液250 ml中,静脉滴注,每日1次。两组患者均治疗14 d后判定疗效并观察治疗前后美国国立卫生院卒中量表(NIHSS)评分、格拉斯哥昏迷(GCS)评分、一氧化氮(NO)含量、一氧化氮合酶(NOS)和诱导型一氧化氮合酶(iNOS)活性,记录治疗过程中的不良反应发生情况。结果:观察组患者总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗前,两组患者NIHSS评分、GCS评分、NO含量、NOS和iNOS活性比较,差异均无统计学意义(P>0.05)。治疗后,两组患者GCS评分均显著高于同组治疗前,且观察组高于对照组;NIHSS评分、NO含量、NOS和iNOS活性均显著低于同组治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在常规治疗的基础上,醒脑静注射液治疗缺血性脑卒中疗效显著,安全性较好,可能与其可降低NO含量和GCS评分有关。
ABSTRACT: OBJECTIVE:To observe the efficacy and safety of Xingnaojing injection in the treatment of ischemic stroke. METHODS: 110 patients with ischemic stroke were randomly divided into control group and observation group. 2 groups were given regulation of blood pressure and blood glucose, lipid lowering, aspirin, citicoline and edaravone, mannitol depending on severity and other conventional treatment. Based on it, control group was intravenously infused 250 ml 0.9% Sodium chloride injection, once a day; observation group was additionally intravenously infused 20 ml Xingnaojing injection, adding into 250 ml 0.9% Sodium chloride injection, once a day. The efficacy was judged after 14 d. US National Institutes of Health Stroke Scale (NIHSS) , Glasgow coma score (GCS), nitric oxide (NO), nitric oxide synthase (NOS), inducible nitric oxide (iNOS) content in 2 groups were observed, and in the incidence of adverse reactions was recorded. RESULTS: The total effective rat in observation group was significantly higher than control group, the difference was statistically significant (P<0.05). Before treatment, there were no significant differences in the NIHSS, NO, NOS and iNOS contents between 2 groups(P>0.05); after treatment, GCS in 2 groups were significantly higher than before, and observation group was higher than control group, NIHSS, NO, NOS and iNOS contents were significantly lower than before, and observation group was lower than control group, the differences were statistically significant(P<0.05). And there was no significant difference in the incidence of adverse reactions between 2 groups(P>0.05). CONCLUSIONS: Based on conventional treatment, Xingnaojing injection has significant efficacy in the treatment of ischemic stroke, with good safety, which may be related that it can reduce NO and GCS.
期刊: 2016年第27卷第6期
作者: 张波
AUTHORS: ZHANG Bo
关键字: 醒脑静注射液;缺血性脑卒中;一氧化氮;疗效;安全性
KEYWORDS: Xingnaojing injection; Ischemic stroke; NO; Efficacy; Safety
阅读数: 409 次
本月下载数: 2 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!